1. QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 405 Active, 290893 Tested
AID: 1706

2. Summary of probe development efforts to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 
AID: 1859

3. QFRET-based confirmation biochemical high throughput screening assay for inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 136 Active, 380 Tested
AID: 1879

4. QFRET-based dose response biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 44 Active, 101 Tested
AID: 1890

5. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 9 Active, 14 Tested
AID: 488958

6. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 15 Active, 32 Tested
AID: 488967

7. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 2
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 10 Active, 103 Tested
AID: 488984

8. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 2
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 3 Active, 4 Tested
AID: 488999

9. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 3
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 3 Active, 6 Tested
AID: 493245

10. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 3
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 5 Active, 10 Tested
AID: 588771

11. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 4
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 14 Active, 28 Tested
AID: 588772

12. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 4
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 3 Active, 10 Tested
AID: 588786

13. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical dose-response assay for inhibitors of 3CLPro; Set 5
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 1 Tested
AID: 602486

14. Late stage assay provider results from the probe development effort to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): fluorescence-based biochemical assay for inhibitors of 3CLPro: Set 5
Source: The Scripps Research Institute Molecular Screening Center
Protein Target: 3C-like protease, partial [Infectious bronchitis virus]
Substance BioActivity: 5 Tested
AID: 602487
